Effect of early high-loading-dose tirofiban on platelet activity in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

Chinese Journal of Cardiology

Volumn 40, Issue 2, 2012, Pages 131-135

  Ren, Xiao Nan ^a   Wang, Le Feng ^a   Wang, Ming Sheng ^b   Xu, Li ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Angioplasty,transluminal,percutaneous coronary; Myocardial infarction; Platelet aggregation inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; TIROFIBAN;

ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT OUTCOME;

AGED; BLOOD PLATELETS; EMERGENCY TREATMENT; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME; TYROSINE;

EID: 84862059170     PISSN: 02533758     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3758.2012.02.011     Document Type: Article

References (19)

1. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein II b/III a inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet, 359: 189-198.
2. 2007, 35: 517-522.
3. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation, 2001, 103: 2572-2578.
4. Batchelor WB, Tolleson TR, Huang Y, et al. Randomized comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes; the COMPARE trial. Comparison of measurements of platelet aggregation with aggrastat, reopro, and eptifibatide. Circulation, 2002, 106: 1470-1476.
5. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein II b/III a inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med, 2001, 344: 1888-1894.
6. Ernst NM, Suryapranata H, Miedema K, et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol, 2004, 44: 1187-1193.
7. Danzi GB, Sesana M, Capuano C, et al. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am J Cardiol, 2004, 94: 35-39.
8. Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction; the multistrategy randomized trial. JAMA, 2008, 299: 1788-1799.
9. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA, 2005, 293: 2109-2117.
10. De Luca G, Ucci G, Cassetti E, et al. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. J Am Coll Cardiol, 2009, 53: 1668-1673.
11. Gurm HS, Tamhane U, Meier P, et al. A comparison of abciximab and small-molecule glycoprotein II b/III a inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials. Circ Cardiovasc Interv, 2009, 2: 230-236.
12. Hobson AR, Agarwala RA, Swallow RA, et al. Thrombelastography: current clinical applications and its potential role in interventional cardiology. Platelets, 2006, 17: 509-518.
13. McCrath DJ, Cerboni E, Frumento RJ, et al. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg, 2005, 100: 1576-1583.
14. Agarwal S, Coakley M, Reddy K, et al. Quantifying the effect of antiplatelet therapy: a comparison of the platelet function analyzer (PFA-100) and modified thromboelastography (mTEG) with light transmission platelet aggregometry. Anesthesiology, 2006, 105: 676-683.
15. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the prepare post-stenting study. J Am Coll Cardiol, 2005, 46: 1820-1826.
16. Miiller I, Seyfarth M, Rüdiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart, 2001, 85: 92-93.
17. Coller BS. Monitoring platelet GP II b/III a antagonist therapy. Circulation, 1998, 97: 5-9.
18. Danzi GB, Capuano C, Sesana M, et al. Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein II b/III a receptor blockers in patients undergoing a high-risk percutaneous coronary intervention. Am J Cardiol, 2006, 97: 489-493.
19. van Werkum JW, Gerritsen WB, Kelder JC, et al. Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial. Neth Heart J, 2007, 15: 375-381.